111955-90-9 Usage
General Description
The chemical compound "(1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside" is a complex molecule composed of a tetracycline core modified with a sugar moiety and an amino group. It has a tetracycline-like structure with a 10-methoxy and 3-amino substituent, as well as a hexopyranoside sugar attached to the C-3 position. (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside is important in the development of novel antibiotics and anticancer drugs due to the potential for targeting specific cellular processes. It is also of interest in the field of medicinal chemistry for its potential in drug design and molecular recognition studies.
Check Digit Verification of cas no
The CAS Registry Mumber 111955-90-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,9,5 and 5 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 111955-90:
(8*1)+(7*1)+(6*1)+(5*9)+(4*5)+(3*5)+(2*9)+(1*0)=119
119 % 10 = 9
So 111955-90-9 is a valid CAS Registry Number.
111955-90-9Relevant articles and documents
Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism
Bains, Onkar S.,Karkling, Morgan J.,Lubieniecka, Joanna M.,Grigliatti, Thomas A.,Reid, Ronald E.,Riggs, K. Wayne
, p. 755 - 763 (2010)
Doxorubicin (DOX) and daunorubicin (DAUN) are anthracycline anticancer agents; however, considerable interpatient variability exists in their pharmacokinetics. This interpatient variability is attributed in part to altered metabolism by nonsynonymous sing
Anthracycline glycoside compositions, their use and preparation
-
, (2008/06/13)
Anthracycline glycoside antibiotics are complexed with cardiolipin and then encapsulated in liposomes to reduce mammalian cardiac tissue uptake of the anthracycline glycoside and to thereby reduce the deleterious effect of such cardiac tissue uptake. The invention is directed to the composition, preparation and use of the encapsulated complex of anthracycline glycoside.
